[
  {
    "id": "1725967364_dermatology_all_pg3",
    "doc_id": "1725967364_dermatology_all",
    "page": 3,
    "text": "These STWs have been prepared by national experts of India\n with feasibility considerations for various levels of healthcare\n system in the country. These broad guidelines are advisory, and\n are based on expert opinions and available scientiﬁc evidence.\n There may be variations in the management of an individual\n patient based on his/her speciﬁc condition, as decided by the\n treating physician. There will be no indemnity for direct or\n indirect consequences. Kindly visit our web portal\n (stw..org.in) for more information.\n © and , \n .",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg4",
    "doc_id": "1725967364_dermatology_all",
    "page": 4,
    "text": "Suggested Citation: Standard Treatment Workﬂows\nof India, 2022, Edition, Vol. 3, New Delhi, , , \n.\n\n© DHR and \n\nAll rights reserved. No part of these workﬂows may be\ntransmitted or reproduced in any form or by any\nmeans without prior permission from the\norganization.\n\nPrinted in India",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg5",
    "doc_id": "1725967364_dermatology_all",
    "page": 5,
    "text": "• INTRODUCTION\n\n• SPECIALITIES COVERED IN THIS EDITION\n\n Dermatology\n Acne Roseacea\n Alopecia\n Bacterial skin infections\n Cutaneous adverse drug reactions Part A\n Cutaneous adverse drug reactions Part B\n Dermatophytosis\n Eczema/Dermatitis\n Immunobullous dermatoses\n Psoriasis\n Rationale use of Topical Steroids\n Scabies\n Urticaria\n Varicella and Herpes\n Vitiligo",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg6",
    "doc_id": "1725967364_dermatology_all",
    "page": 6,
    "text": "GOAL \n\nTo empower the primary, secondary and tertiary health care\nphysicians/surgeons towards achieving the overall goal of\nUniversal Health Coverage with disease management protocols\nand pre-deﬁned referral mechanisms by decoding complex\nguidelines.\n\nOBJECTIVES\nTo formulate treatment algorithms for common and serious\nmedical & surgical conditions for both outdoor & indoor patient\nmanagement at primary, secondary and tertiary levels of India’s\nhealthcare system that are scientiﬁc, robust and locally\ncontextual.\nMETHODOLOGY\n\n Speciality\n wise Expert\n Committees\n\n ADVISORY \n COMMITTEE STW Team\n\n Editorial\n Output Board\n\n Mobile Web\n Book\n Apps Portal\n\nPROCESS OVERVIEW\n\n • Participation also from Public DEVELOP STWS\n Health Specialists Search CONVERT THEM\n Strategists Graphic Designers INTO\n INFOGRAPHICS\n\n TOPIC\n PRIORITIZATION\n\n REVIEW OF\n CURRENT • Review by Editorial Board\n GUIDELINES & • Approval by Advisory • Prevalence studies\n FEASIBILITY AS Committee • Global burden of\n PER HEALTH diseases studies\n SYSTEM • HBP of AB-PMJAY",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg8",
    "doc_id": "1725967364_dermatology_all",
    "page": 8,
    "text": "2022\n\n Standard Treatment Workﬂow (STW)\n ACNE AND ROSACEA\n ICD-10-L70-71\n\n Acne is a common dermatosis of adolescence and often persists into adulthood\n\n Rosacea often mimics acne but has distinct management issues\n\n WHEN TO SUSPECT? USEFUL INFORMATION\nACNE ROSACEA • Acne and rosacea can\n • Comedones (open-blackheads, • Photosensitivity co-exist\n • It is important to treat acne closed-whiteheads) ± any one or • Persistent erythema, telangiectasia ± papules\n early so that scarring is\n more of the following and pustules in absence of comedones minimal\n > Papules, pustules • In Indian scenario, consider • Sites: Convexities of the face (cheeks, forehead,\n > Painful nodules containing pus ‘topical corticosteroid\n nose, chin) > induced acne and rosacea’ Cysts\n • Bulbous enlargement of nose- rhinophyma\n > Scarring\n • Symptoms: Sensitivity to hot and spicy food, and • Sites: Face and/or trunk\n emotional triggers • Symptoms: None/pain/pricking\n\n ADDITIONAL INFORMATION FOR CLINICAL EVALUATION\n• History of cosmetics/topical steroid use- as such, or in combination • History of menstrual irregularities (oligomenorrhea),\n with creams/fairness creams weight gain and hirsutism- look for polycystic ovarian\n• Age of onset usually around puberty; onset before 8 years of age syndrome\n requires hormonal evaluation • History of premenstrual ﬂare\n• History of recent drug intake (>fortnight/ month)- Drug induced acne • Persistence or onset/ recurrence after 25 years of age\n• History of contact with cutting oils/ halogens (ingestion of iodides/ • History of dry and gritty eyes- requires\n bromides) ophthalmologic evaluation for ocular rosacea\n\n ACNE VARIANTS AND DIFFERENTIALS DIFFERENTIALS OF ROSACEA\n• Acne conglobata: Severe scarring on trunk and face with nodular • Connective tissue diseases like lupus\n lesions erythematous or dermatomyositis:\n• Drug induced acne (with corticosteroids/ antiepileptic drugs/\n Photosensitivity, presence of Raynaud’s\n antitubercular drugs/ vitamin and protein supplements): Extensive,\n phenomenon, arthralgia, muscle weakness, monomorphic papules and pustules in absence of comedones\n dyspnea, dysphagia, oral/ genital ulcers, abdominal• Topical corticosteroid induced acne: Hypertrichosis, shiny, thin skin,\n pigmentary changes with papulo-pustules pain, frothy urine, seizures, or alopecia\n• Hormonal acne: Adult female with seborrhea, hirsutism, androgenetic • Steroid induced rosacea: Photosensitivity,\n alopecia, insulin resistance and PCOS, premenstrual ﬂare, menstrual\n hypertrichosis, atrophy and pigmentary changes, irregularities and prominent involvement of mandibular area\n prior history of topical corticosteroid application for• Occupational acne: Predominantly comedones with history of\n exposure to cutting oil/ petroleum products a long time\n• Acne excoriee: Predominantly picked and excoriated lesions with • Seborrheic dermatitis: Predominant involvement\n prominent pigmentation\n of nasolabial folds, eyebrows with erythema and\n• Acne fulminans: Fever and bone pains in association with severe\n greasy scales necrotic acne lesions\n• Hidradenitis suppurativa: Association to consider when axillae/groins/ • Contact dermatitis or atopic dermatitis:\n other ﬂexures are involved with polyporous comedones/ pustules/ Signiﬁcant itching, exudation and crusting\n nodules/ abscesses/ scarring\n\n ACNE VULGARIS ACNE EXCORIEE DRUG INDUCED ACNE NODULOCYSTIC ACNE ROSACEA\n MANAGEMENT\n ACNE ROSACEA\n• Stop unsupervised topical corticosteroid and cosmetic use on face • Avoid triggers (alcohol, caffeine, spicy\n• Clean face with soap/ mild cleanser food, cosmetics, topical steroids)\n• Mild-moderate acne: 2.5% Benzoyl peroxide gel or 0.025% Tretinoin cream or • Photoprotection\n 1% Adapalene gel ± Clindamycin gel for local application, at night time • Mild papulopustular rosacea: topical •\n• Moderate acne, not controlled with topicals: Cap Doxycycline 100mg OD for Azelaic acid (15%) or Metronidazole\n minimum of 4-6 weeks (1%) or Ivermectin (1%)\n• Severe nodulocystic acne: Isotretinoin treatment at tertiary level after • Moderate disease, not controlled with\n documentation of normal lipid proﬁle and liver functions topicals: Cap Doxycycline 100mg OD\n• Acne fulminans: start Prednisolone 0.5-1 mg/kg/day and refer to higher center for minimum of 4-6 weeks\n• Hormonal acne: Treatment with anti-androgens at tertiary level • Severe/phymatous/ ocular rosacea:\n• Drug induced acne: Stop offending drugs if feasible; treatment as per severtiy refer to a specialist for low dose\n as detailed above Isotretinoin/interventional treatment\n\n TREAT ACNE EARLY TO PREVENT SCARRING",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg9",
    "doc_id": "1725967364_dermatology_all",
    "page": 9,
    "text": "y/\n 2022\n\n Standard Treatment Workﬂow (STW)\n ALOPECIA / HAIR LOSS\n ICD-10-L63.9\n DEFINITION\n Excessive hair HISTORY AND EXAMINATION GENERAL HAIR CARE PRINCIPLES\n shedding and/ Elicit history pertaining to Examine scalp for • Hair fall of upto 100 per day may\n or sparsening • Duration and age of onset of hair loss be normal and need not cause scarring vs non-scarring leading to • Whether patchy or diffuse scalp alarm\n visible scalp by looking for involvement, and if other hair bearing • Regular cleaning of scalp and\n that may be\n areas are affected • Loss of skin markings hair with plain shampoo\n either patchy • Relevant medical history pertaining to • Avoid hair oil application and\n or diffuse • Loss of hair follicle ostia speciﬁc entities mentioned below damaging mechanical/\n • Hair care practices including cosmetic • Pigmentary changes chemical hair care procedures\n hair procedures\n\n NON SCARRING ALOPECIA (SMOOTH BALD AREAS WITH SMALL BLACK INTACT HAIR FOLLICLES)\n\n CONGENITAL ACQUIRED\n\n Patchy Diffuse\n\n Telogen efﬂuvium Pattern hair lossAlopecia due to inherited/\n\ncongenital disorders with\nor without easy hair • History to rule out underlying medical\n illness, drug intake, menstrual irregularities,\nbreakage\n hypo/ hyperthyroidism, anemia, physical/ Androgenetic Female pattern\n • Congenital mental stress alopecia: males hair loss\n hypotrichosis • Labs- Hemogram, and if indicated serum\n ferritin, TSH\n • Monilethrix\n • Reassurance and treatment of underlying • Hair thinning with widening of partition\n • Trichorrhexis nodosa disorder. If persistent, consider 1 ml of 5% usually in postmenopausal women\n topical Minoxidil once a day • Loose anagen hair • In premenopausal, look for signs of\n hyperandrogenism. If present, hormonal syndrome\n • Adult males with fronto-temporal hairline thinning workup to rule out PCOS or virilising\n • Woolly hair syndrome or recession, it may progressively involve vertex & tumors of ovary/ adrenal glands\n parietal areas with usual sparing of occipital area • 1 ml of 5% Minoxidil solution OD for local\n • Treat with 1mL of topical 5% Minoxidil solution BD application Refer to tertiary centre for\n • If effective continue this treatment to maintain hair • Treatment of underlying condition further evaluation\n growth • Severe non-responsive: refer to tertiary\n • Addition of oral Finasteride 1 mg/day may be care\n considered • Oral anti-androgens (Finasteride,\n • Can be referred to trained specialist for hair Spironolactone, cyproterone acetate\n transplant, if required with oral contraceptives may be added)\n\n Tinea capitis Trichotillomania Alopecia areata\n\n• Asymptomatic, single/ multiple smooth bald patches; • Children with patches of hair loss • Children or young adults with\n can progress to involve whole scalp (alopecia totalis) with scaling and/ or signs of bizzare shaped bald patches\n or all body hairs (alopecia universalis) inﬂammation (erythema, with broken hair of different\n• H/o atopy, examine for nail pitting pustulation, boggy swelling). Easy length and focal scalp\n• <50% of scalp: Topical 0.05% Betamethasone lotion pluckability of hair within the patch\n hemorrhages OD, intralesional Triamcinolone once in 2-4 weeks ( 5 • KOH mount for conﬁrmation, if\n • Look for other signs of impulsive mg/ml for scalp and 2.5 mg/ml for beard or eyebrows) available\n only for limited involvement, topical Minoxidil 5% OD • Oral antifungals- Griseofulvin 10-20 behaviour\n• >50% of scalp or involvement of facial and body hairs mg/kg, Terbinaﬁne 5 mg/kg; for 6-8 • Counselling and referral to\n or margin of occipital area: refer to tertiary centre to weeks psychiatrist if needed\n be worked up for immunosuppressants such as oral • Topical antifungal shampoos\n steroids mini pulse, Methotrexate or Cyclosporine • Avoid comb sharing\n\n SCARRING ALOPECIA (AREAS WITH FIBROSIS AND DAMAGE TO HAIR FOLLICLES)\n All cases of scarring alopecia must be referred to a dermatologist for histological conﬁrmation & further management\n\n Primary\n Secondary\n\n Due to trauma/ burns/ dermatoses\n Pustules or Pigmentary like morphea, pemphigus,\n boggy lesions changes neoplasms affecting the scalp\n\n Folliculitis Lichen plano pilaris Discoid lupus\n erythematosus Investigation decalvans Violaceous plaques\n Erythematous to and treatment and follicular plugs. Dissecting depigmented plaques of underlying Examine for lichen\n cellulitis of with atrophy, scaling disorder planus of other sites scalp and follicular plugs\n\n Investigations: Investigations: Investigations:\n • Trichoscopy, scalp biopsy for • Trichoscopy, scalp biopsy for histopathology • Trichoscopy, scalp biopsy for\n histopathology Treatment: histopathology, direct immunoﬂuorescence,\n Treatment: • Oral steroid mini pulse +/- Methotrexate/ workup to rule out SLE\n Treatment: • Long term oral antibiotics: Azathioprine/ Cyclosporine for halting active\n • Photoprotection Doxycycline/ Clindamycin for progression\n • Topical steroids 10-12 weeks • Strict laboratory monitoring for any adverse\n • Hydroxychloroquine 5mg/kg/day after\n • Consider low dose oral steroids drug events\n baseline ocular examination; usually\n • Isotretinoin • For burnt out disease- wigs and camouﬂage required for 6-12 months\n\n HIGH REGROWTH POTENTIAL WITH NON-SCARRING ALOPECIA, GUARDED REGROWTH POTENTIAL WITH SCARRING ALOPECIA",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg10",
    "doc_id": "1725967364_dermatology_all",
    "page": 10,
    "text": "022\n\n Standard Treatment Workﬂow (STW)\n BACTERIAL SKIN INFECTIONS\n ICD-10-L01, L73.9, L08, L02, L03, A46, L00\n\n Skin hygiene, advise on 1. IMPETIGO\n handwashing/ local hygiene, CLINICAL FEATURES\n avoidance of oil application, Wet yellow brown crusts overlying red inﬂamed skin\n adequate nutrition • Types Non bullous (NBI; commoner), bullous (BI)\n For recurrent/ severe lesions: • Affected age group usually children\n evaluate for nasal carriage, • Common sites Face (perinasal, perioral) > extremities; extensive GENERAL diabetes, underlying skin with scabies/ atopic eczema\n PRINCIPLES OF conditions (scabies, atopic\n MANAGEMENT dermatitis) MANAGEMENT\n In immunocompromised/ • Topical antibiotics for 5 days\n diabetics: consider the need • Oral antibiotics for extensive involvement or numerous lesions,\n for gram negative coverage lymphadenopathy or in outbreaks to prevent transmission\n\n 2. ECTHYMA 3. FOLLICULITIS\n CLINICAL FEATURES CLINICAL FEATURES MANAGEMENT\n • Black thick crust (eschar) with underlying ulcer Hair follicle centred pustule/ papule • Topical antibiotics for 5 days\n & surrounding redness & edema Rule out non bacterial causes: oils, chemicals, • Oral antibiotics for multiple\n MANAGEMENT waxing, epilation, occlusive dressing lesions\n • Treat with oral antibiotics for 7 days RECURRENT FOLLICULITIS Recurrent infection or • Anti-inﬂammatory: Paracetamol\n • Gentle crust removal may be attempted after outbreak in multiple members of family may\n 500mg/ Ibuprofen 400mg SOS soakage with sterile saline; topical antibiotics indicate nasal Staphylococcus aureus\n over the exposed ulcer carriage or human-pet transmission for pain relief\n\n 4. FURUNCLE 5. CARBUNCLE 6. CUTANEOUS ABSCESS\n CLINICAL FEATURES Painful follicle centric CLINICAL FEATURES Conﬂuence of multiple closely CLINICAL FEATURES Painful, warm, red\n nodule/ pus point/ impending bulla/ spaced furuncles + pus draining from multiple ﬂuctuant skin swelling\n ulcer with marked surrounding follicular oriﬁces\n erythema, edema and induration Commonly nape of neck> breasts, buttocks in\n uncontrolled diabetes\n\n SMALL LARGE INCISION AND DRAINAGE HOSPITALIZATION AND IV TREATMENT FOR\n • Oral antibiotics + • Incision and drainage/ debridement SEVERELY ILL PATIENTS\n • Topical antibiotics: • Ancillary antibiotics if systemic • Inj Ceftriaxone 2g BD OR Inj\n to reduce inﬂammatory signs, associated septic Amoxicillin-clavulanate 1.2gm TDS\n phlebitis, multiple/ large abscesses, contamination of • Alternatively - Inj Clindamycin\n prominent cellulitis &\n surrounding skin 600-900mg TDS MANAGEMENT immunocompromised state\n\n IMPETIGO ECTHYMA FOLLICULITIS FURUNCLE CARBUNCLE\n\n 7. CELLULITIS 8. ERYSIPELAS\n CLINICAL FEATURES Acute spreading CLINICAL FEATURES A more superﬁcial, bright red, edematous, painful\n infection of skin involving subcutaneous area with a clear demarcated edge; common sites: lower\n tissue; Painful, red, tender, diffuse extremities>face. Often associated with lymphangitis and\n swelling mostly involving the limbs lymphadenopathy; broken skin/ portal of entry may be visualised CELLULITIS WITH BULLAE\n\n MILD MODERATE SEVERE\n • Typical cellulitis/ erysipelas • Typical cellulitis/ erysipelas with With poor response to oral antibiotics,\n with no focus of purulence immunocompromised, signs of deeper systemic signs of infection\n MANAGEMENT infection like bullae, skin sloughing or\n MANAGEMENT • Outpatient treatment with oral systemic signs of infection like hypotension, SEVERITY Hospitalization and parenteral antibiotics or with organ dysfunction\n • Elevation of affected area (to antibiotics: MANAGEMENT\n allow for dependent drainage); • Inj Ceftriaxone 2g BD OR Empiric broad spectrum IV antibiotic DISEASE\n treatment of predisposing Inj Amoxicillin-clavulanate 1.2gm coverage\n factors • Vancomycin + Piperacillin/ tazobactum MANAGEMENT TDS\n • Anti-inﬂammatory (Ibuprofen • Surgical debridement • Alternatively (allergic to penicillins)\n 400mg BD, Indomethacin • Sensitivity proﬁle based modiﬁcation of\n Inj Clindamycin 600-900mg IV TDS CATEGORIZE 75mg BD) antibiotics\n\n INVESTIGATIONS COMPLICATIONS\n 1. Swabs for gram staining and pus culture are desirable Subcutaneous abscesses, blistering\n 2.Blood cultures and biopsies are not routinely recommended, but useful with co-morbid (often haemorrhagic), ulceration,\n conditions (malignancy on chemotherapy, immunocompromised states, animal bites etc.) tissue necrosis, myositis, septicemia\n\n 9. STAPHYLOCOCCAL SCALDED SKIN SYNDROME RED FLAGS\n • Superﬁcial peeling of skin due to toxin producing strains of staphylococcus • Temperature >100.4 ºF,\n • Starts as tender and warm erythema and progresses to localised or generalised WBC>12,000 or < 4000/μL, heart\n exfoliation with fever, malaise +/- dehydration and electrolyte disturbances rate > 90 bpm, or respiratory rate\n • Follows a local staphylococcal infection of either skin, throat, nose, umbilicus, or gut > 24/min may indicate sepsis\n • Bacteria cannot be demonstrated from blisters (cultures from original site may be • Severe pain followed by deceptive\n positive) absence may indicate necrotising\n • Treatment: preferably in-patient fasciitis\n • Mild cases: oral anti-staphylococcal antibiotics; severe cases: IV antibiotic • Dark discoloration of overlying\n • Consider methicillin resistant Staphylococcus aureus (MRSA) coverage skin\n • Usually remits within a week in children, high mortality in adults\n\n PHARMACOTHERAPY\n\n FOR NASAL CARRIERS IN ALL PATIENTS SUSPECT THE NEED FOR MRSA COVERAGE IF: ANTIBIOTICS FOR SKIN AND SOFT TISSUE INFECTIONS\n 2% Mupirocin ointment • Poor immune status\n • Severe systemic signs for 5 days a month\n • MRSA infection elsewhere PREFER β-LACTAMS IF ALLERGIC TO • If no improvement in 48-72 hours\n• Amoxycillin 500mg TDS PENICILLINS TOPICAL • Penetrating trauma\n (25-50 mg/kg/day) • Erythromycin ANTIBIOTICS\n• Cloxacillin 500mg QID 500mg QID (40 • Mupirocin ORAL ANTIBIOTICS FOR SUSPECTED IV ANTIBIOTICS FOR MRSA\n (50mg/kg/day) mg/kg/day) cream 2% OR CONFIRMED MRSA INFECTION • Vancomycin: 15 mg/kg BD\n• Cephalexin 250-500mg • Clindamycin: • Fusidic acid • Cotrimoxazole 2 DS tablets BD • Linezolid: 600 mg BD\n QID (25–50 mg/kg/day) 300-600mg cream 2% • Doxycycline 100 mg BD • Clindamycin: 600-900 mg\n• Amoxicillin clavulanate BD/TID • Framycetin • Minocycine 200 mg BD\n TDS\n combination: 625mg TDS (20mg/kg/day) cream 1% • Linezolid 600 mg BD\n\n ANTIBIOTIC SUSCEPTIBILITY PATTERNS MAY VARY WITH REGION AND TIME",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg11",
    "doc_id": "1725967364_dermatology_all",
    "page": 11,
    "text": "022\n\n Standard Treatment Workﬂow (STW)\n CUTANEOUS ADVERSE DRUG REACTIONS- PART A\n ICD-10-L27.0\n\n Cutaneous adverse drug reactions (cADR) are undesirable clinical manifestations to a drug, which include predictable or\n unanticipated side effects, with or without systemic involvement\n\n COMMON TYPES OF cADR\n NON- SEVERE cADR SEVERE cADR\n\n Fixed drug Maculopapular/ Drug induced Acute generalized Erythema multiforme/ Angioedema/\n eruption Exanthematous hypersensitivity exanthematous Stevens Johnson syndrome/ Anaphylaxis*\n (FDE) reactions syndrome/ DRESS* pustulosis Toxic epidermal necrolysis*\n\n *Refer to separate STW on Urticaria/ Angioedema, and cADR Part-B for DRESS/ Stevens Johnson syndrome/ Toxic epidermal necrolysis\n TIMELINES FOR DRUG REACTIONS\n GENERAL PRINCIPLES HISTORY ELICITATION\n AND SOME TYPICAL EXAMPLES\n\n • Common presentation: Sudden onset of an itchy rash that is • History of prior adverse ∙ 5-15 minutes: Anaphylaxis,\n symmetrically distributed and spreads rapidly. May have had a drug reaction urticaria, angioedema\n previous similar allergic reaction.\n • Patients on polypharmacy: ∙ Few hours: Reactivation of ﬁxed • Withdraw: The offending drug(s) immediately, except life saving\n drugs (if they are not the suspected drugs) list all recently introduced drug eruption\n • Take necessary measures to prevent similar events (record on drugs and/ or dosage ∙ Few hours- 2 weeks:\n patient’s medical chart, educate, provide allergy card etc.) increments. However, all Maculopapular exanthem,\n • Recognize danger signs drugs should be kept in erythema multiforme, Stevens\n » Mucosal lesions, purpuric lesions, skin tenderness, bullous\n suspect list –Johnson syndrome, toxic lesions (peeling/ sloughing of skin)\n » Systemic symptoms: High grade fever, jaundice, decreased • Concomitant viral infection epidermal necrolysis, ﬁrst episode\n urine output or illnesses affecting drug of FDE\n • Action required: Prompt and urgent care at a specialised centre. metabolism or excretion ∙ 4- 12 weeks: DRESS syndrome,\n Apart from maintenance of vitals, withdrawal of all drugs, (eg. chronic kidney Dapsone syndrome, anticonvulsant\n initiation of oral or intravenous corticosteroids, care of the eye,\n disease) induced hypersensitivity syndrome evaluation of secondary infection/ sepsis are important\n\n 1) FDE\n • Distinctive drug eruption: usually recur at the same site on drug re-exposure REFER TO HIGHER CENTER IF\n • Acute FDE: dusky red-violaceous plaques with or without vesiculation or bullae\n • There are atypical symptoms • Common sites: lip, genitalia, proximal extremities, low back, sacrum\n • Uncertain diagnosis • Local symptoms: pruritus, burning, and pain; solitary or numerous (latter is difﬁcult to\n differentiate from toxic epidermal necrolysis). Resolve with persistent hyperpigmentation • Severe reaction (multiple lesions,\n • Clinical variants: bullous, generalised, pure mucosal bullae, severe mucosal lesions,\n • Common drugs that cause FDE: Sulfonamides, tetracyclines, quinolones, NSAIDS, dapsone, systemic symptoms)\n antimalarials, barbiturates, nitroimidazoles\n MANAGEMENT\n\n PRIMARY HEALTH CENTRE TERTIARY LEVEL SECONDARY LEVEL CARE\n • Withdraw the drug • Admit the patient if the episode is generalized and • Continue treatment as\n • General management: Bullous/ moist/ oozy severe described at primary\n lesions- normal saline compresses care level • Histopathology in doubtful cases • Topical steroid: Betamethasone valerate cream\n • If severe: add short • If the oral mucositis is severe, consider parenteral steroids BD for cutaneous lesions\n course of oral steroids: • Provocation tests may be done after resolution of • Antihistamines –Tab Pheniramine maleate 25\n Prednisolone 0.5 mg-1 symptoms (usually after 1-6 months) by an oral challenge mg BD/TID for itching\n • Review patient in 1 week mg/kg for 3-5 days with each suspected individual drug consecutively\n\n 2) MACULOPAPULAR/EXANTHEMATOUS REACTIONS\n\n• Abrupt onset, erythematous maculopapular eruption\n RED FLAG SIGNS• Typically starts on the trunk, spreads symmetrically to extremities. Dependent areas may have\n • Mucosal involvement purpuric lesions\n • Purpuric lesions• Usually accompanied by mild systemic symptoms- pruritus, low grade fever, mild eosinophilia\n • Bullous lesions• All drugs taken in the last 4 weeks are suspects. May manifest within 48 hours if the patient has\n • Skin tenderness taken the drug previously\n • Facial/ acral edema• Commonly observed with co-trimoxazole, cephalosporins, anti-tubercular drugs,\n • Erythroderma aminopenicillins, quinolones, dapsone, NSAIDS, anticonvulsants, nevirapine, abacavir,\n • Systemic symptoms - High allopurinol, leﬂunomide\n grade fever, hepatitis, renal• Differential diagnosis: Viral exanthem, Rickettsial rash, HIV, Kawasaki disease (in children)\n involvement, signiﬁcant• Fever and prodromal symptoms (coryza, malaise) occur before the development of rash in most\n eosinophilia viral exanthems and the drug history is usually negative prior to it\n\n MANAGEMENT\n\n PRIMARY CARE SECONDARY CARE TERTIARY CARE\n• Withdraw the suspect drug(s) • Conﬁrm the diagnosis by history and clinical ﬁndings • Admit if red ﬂag signs are present\n• Pheniramine maleate 25 mg TID • Admit if red ﬂag signs are present • Conﬁrm diagnosis of drug rash\n• Calamine lotion • Laboratory tests: CBC (Eosinophilia supports the • Additional lab tests if required: ANA, HIV,\n• Refer to higher center if diagnosis), LFT, serum creatinine, urine M/E skin biopsy\n symptoms persist or red ﬂag • Treatment: in severe cases, prednisolone 0.5-1 mg/ kg/ • Consider DRESS if rash is progressing or\n signs present day x 5-7 days (after ruling out infection) signiﬁcant organ involvement is evident\n\n DRUG PROVOCATION TEST\n In the absence of any reliable in vitro test in clinical setting, oral drug challenge is the only way to detect the responsible drug\n\n Usually undertaken when drug avoidance is impractical, • Drug provocation should always be done\n especially in case of polypharmacy or life saving medicines - After admission/ under observation except in cases with\n (e.g. antituberculous therapy) FDE\n - Usually in the daytime so that the faintest erythema is\n appreciated • Take a written consent prior to challenge\n - It should be treated immediately and aggressively with • Contraindicated in active illness or pregnancy\n an appropriate dose of systemic corticosteroid which • Assess the risk beneﬁt ratio\n may be required for only 1-2 days\n • Caution: patients on antihistamines, oral steroids and tricy- - Drug provocation in cases with DRESS has to be avoided\n clic antidepressants may have a modiﬁed response to the or if provoked, a prolonged retreatment is required\n challenge - In case of SJS-TEN drug provocation should be done\n • A negative test only indicates that the patient is not allergic only if the drug cannot be avoided. Provocation is preto the drug at the time of challenge ferred with a chemically unrelated molecule\n • The dose of drug for challenge depends on the severity of • Intradermal tests can be done in IgE mediated reactions\n the previous reaction and the pharmacokinetic proﬁle • Patch test has a low sensitivty and should not be relied upon\n in severe cADR\n\n FDE BULLOUS FDE MACULOPAPULAR RASH",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg12",
    "doc_id": "1725967364_dermatology_all",
    "page": 12,
    "text": "/\n 2022\n\n Standard Treatment Workﬂow (STW)\n CUTANEOUS ADVERSE DRUG REACTIONS- PART B\n ICD-10-L27.0\n\n Cutaneous adverse drug reactions (cADR) are undesirable clinical manifestations to a drug, which include predictable or\n unanticipated side effects, with or without systemic involvement.\n\n COMMON TYPES OF cADR\n NON- SEVERE cADR SEVERE cADR\n Fixed drug Maculopapular/ Drug induced Acute generalized Erythema multiforme/ Angioedema/\n eruption Exanthematous hypersensitivity exanthematous Stevens Johnson syndrome/ Anaphylaxis*\n (FDE)* reactions* syndrome/ DRESS pustulosis Toxic epidermal necrolysis\n\n *Refer to separate STW on Urticaria/ Angioedema, and cADR Part-A for FDE/ Maculopapular/ Exanthematous reactions\n\n DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) SYNDROME\n • Potentially life threatening systemic adverse reaction When to suspect DRESS syndrome\n • Exposure to a high risk drug • Onset 2-6 weeks after start of drug intake (up to 12 weeks)\n • Clinical presentation: fever (>38°C-40°C), rash, leukocytosis with eosinophilia,\n • The rash may continue to progress weeks to months after\n lymphadenopathy, hepato-renal dysfunction\n discontinuation of the drug • Features of the rash: involves >50% body surface area, facial edema,\n • Commonly observed with anticonvulsants, dapsone, desquamation or dusky erythema\n allopurinol, abacavir, leﬂunomide, minocycline • Occasionally pustules and targetoid lesions may be seen\n\n MANAGEMENT\n\n PRIMARY CARE SECONDARY CARE TERTIARY CARE\n • Withdraw drugs • Same as primary care • Same as primary/ secondary care\n • Assess vitals, • CBC, absolute eosinophil count (optional), LFT, renal function- • Second line - Cyclosporine (if the renal\n stabilise the monitored at least weekly\n function is normal) patient and refer • CXR, ECG and ECHO to rule out myocarditis\n to higher center • Treatment • Management will require a multidisciplinary\n • If no evidence of major organ involvement • Symptomatic team approach, depending on the organ(s)\n • First line- Systemic steroids- Prednisolone 0.5-2 mg/kg, slow relief: involved taper after symptoms and signs resolve (over months if Antihistamines,\n needed) • In the presence of severe liver failure,\n emollients\n • Antihistamines-Pheniramine 25 mg TID, bland emollients like hemophagocytic syndrome, gastrointestinal • Do not add any liquid parafﬁn\n unnecessary new bleeding, multiorgan failure, the patient may • If there is severe organ involvement- liver, renal or cardiac refer\n medications to tertiary center for multidisciplinary intensive care require intensive care treatment\n\n STEVENS JOHNSON SYNDROME (SJS) AND TOXIC EPIDERMAL NECROLYSIS (TEN)\n • Acute, severe mucocutaneous reactions associated with epidermal WIDESPREAD ATYPICAL TARGETS TYPE DETACHMENT (% BSA)\n detachment and/ or tenderness, and widespread erythematous *OR ERYTHEMATOUS MACULES\n lesions with central dusky erythema or vesiculation often SJS <10% Present\n associated with high grade fever SJS-TEN 10-30% Present\n • Usually observed with aromatic anticonvulsants, allopurinol, TEN ≥30% Present\n nevirapine, abacavir, NSAIDs, co-trimoxazole TEN without SPOTS ≥10% Absent\n • The classiﬁcation of SJS, TEN is based on the extent of detachment *Atypical targets (Red macules with purpuric\n • D/d-Staphylococcal scalded skin syndrome, pemphigus vesiculations/ crusted centers)\n\n TOXIC EPIDERMAL NECROLYSIS\n\n PROGNOSIS\n Assess prognosis with a SCORTEN score done within 24 hours SCORTEN PROGNOSTIC FACTORS POINTS\n of presentation and repeated 3 days later\n Age > 40 years 1\n SCORTEN SCORE ESTIMATED MORTALITY % Tachycardia > 120 bpm 1\n Neoplasia 1 0-1 3\n Initial detachment > 10% 1 2 12\n Serum urea > 60 mg/dL 1 3 35\n Serum bicarbonate < 20mmol/L 1 4 58\n Blood glucose > 252mg/ dL 1 ≥ 5 > 90\n\n INVESTIGATIONS\n • Chest X- ray • Microbiology- Pus culture from infected areas and blood culture\n • ECG • Skin biopsy- Not usually required unless the diagnosis is in doubt\n • Laboratory tests- CBC, LFT, KFT, electrolytes, magnesium, • Optional- In TEN, biopsy and direct immunoﬂuorescence is useful to\n phosphate, lactate\n rule out SLE and pemphigus • Blood gas analysis\n MANAGEMENT\n SECONDARY CARE TERTIARY CARE PRIMARY CARE • Assess vitals, stabilise the patient, nutrition and ﬂuid replacement as appropriate • Admit in specialized• See primary • Local care for skin and mucosae\n care for drug • Skin care- dilute potassium permanganate baths/ saline compresses/ Chlorhexidine baths units within\n ▶ Detached epidermis can be left in situ and covered with non-adherent dressing (sterile dermatology wards if rash with\n vaseline gauze) vitals are stable and eosinophilia ▶ Topical antibiotics (Mupirocin or Fucidin) on sloughed off areas\n follow secondary care and systemic ▶ Oral care- Rinse mouth with Chlorhexidine 2-3 times, soft parafﬁn on lips as needed, steroid\n symptoms mouth washes treatment\n ▶ Eye care- refer to ophthalmologist • Barrier nursing (DRESS)\n • Antibiotics-broad spectrum antibiotics (in case of sepsis or secondary infection) to cover staph, • If patient has SIRS/ sepsis\n strep and pseudomonas. Change according to culture results and avoid suspected drug class\n or in shock, admit to ICU • Adjuvant systemic therapy (ideally within the ﬁrst 24-72 hours of onset)\n ▶ The role of systemic steroids is limited to early phase of SJS/TEN. High doses for longer periods • Long term follow up will\n can increase the risk of sepsis and metabolic complications. However judicious use of be required to address\n Prednisolone 1-2 mg/kg or equivalent dose of intravenous Dexamethasone for 3-7 days may be complications:\n of beneﬁt\n ophthalmic, skin and ▶ Cyclosporine in a dose of 3-5 mg/kg for a period of 10-14 days (with monitoring)\n • If skin detachment >10% refer to a center with an ICU familiar with management of skin failure respiratory tract\n • If < 10% follow the treatment as described involvement\n ANY DRUG BELONGING TO ANY MEDICINAL SYSTEM CAN CAUSE cADR",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg13",
    "doc_id": "1725967364_dermatology_all",
    "page": 13,
    "text": "2022\n\n Standard Treatment Workﬂow (STW)\n DERMATOPHYTOSES\n ICD-10-B35.9\n\n DEFINITION ADVISE ALL PATIENTS TO\n • Superﬁcial fungal infection caused by • Take treatment regularly as advised and never stop without consultation after obtaining\n dermatophytes some relief to prevent relapse\n • Affects keratin bearing structures i.e the • Do not self medicate. This can make the infection difﬁcult to treat\n skin, nails and hair • Do not ever use any steroid containing OTC creams from chemists/ on own\n\n TINEA CORPORIS/CRURIS TINEA PEDIS/ MANUUM ONYCHOMYCOSIS\n\n EXAMINATION EXAMINATION EXAMINATION\n • Itchy scaly lesion on the skin • Dermatophytic infection of palms (Tinea • Discoloration of nail with build up of\n • Typically annular (ring like) lesions with manuum)and soles (Tinea pedis) keratinous debris under the nail\n variable scaling (ﬂaking) and erythema • Generally unilateral involvement; toe webs plate\n (redness) commonly involved • Generally affects isolated nails • Always examine: groins, buttocks, nails, palms • Scaling may present along the creases of asymmetrically and soles palms/soles only or may be diffuse;\n • Ask for lesions in other family members • The whole nail may crumble in\n occasionally dried vesicles are seen\n advanced cases\n • A scaly (+/- erythema) margin may be seen\n • Look for simultaneous involvement\n at the level of wrist\n of palms/soles (T. manuum) and at insteps or out steps of\n • Ask for diabetes; signs of peripheral feet (T.pedis)\n vascular disease • Coexistent involvement of nails is\n common\n\n DIAGNOSIS\n • For doubtful cases: KOH\n microscopy of scales\n shows the typical septate\n hyphae\n • Culture and other\n advanced methods are\n GENERAL MEASURES not required in routine\n • Prolonged treatment is required; practice\n • Treatment with adequate dosage for\n GENERAL MEASURES\n recommended duration should be adhered\n ADVISE THE FOLLOWING DOS AND DONTS to\n TO THE PATIENT • Advise patient to:\n DOS DON'TS Avoid walking barefoot in public places\n esp swimming pools/ community\nTake daily bath with regular Do not bathing areas\nbathing soap and normal share Wash feet with bathing soap and\n GENERAL MEASUREStemperature tap water towels and normal temperature tap water\n clothes Wipe and dry well with a towel • ADVISE PATIENTS TO:\n Dry toe clefts before wearing Keep affected nails trimmed as\nDry skin well after bath Do not shoes/socks they are fragile and trauma prone re-wear Wear cotton socks\nWash clothes separately in clothes Keep separate nail clippers\n Wash worn socks separately in hothot water and dry inside out before Avoid any cosmetic nail waterin the sun washing\n procedures, pedicure/manicure\n TREATMENT • Inform the patient that it might take TREATMENT\n SYSTEMIC TREATMENT several months after treatment TOPICAL ANTIFUNGAL • ALWAYS TREAT TILL ALL LESIONS HAVE\n • For limited involvement in cases of Tinea completion for a completely normal\n COMPLETELY RESOLVED\n corporis and cruris looking nail to appear and in severe\n • This may take between 3-8 weeks or more • USE cases, a cosmetically acceptable depending on the extent of infection and Clotrimazole 1%/2% cream BD\n previous treatments used; longer when result may not be achieved Miconazole 2% cream BD\n Terbinaﬁne 1% cream BD palms/soles also involved or history of\n It is important to treat Ketoconazole 2% cream BD prolonged steroid use\n the nail infection as it is a • For extensive disease,it is not feasible to use • Follow up regularly every 2 weekly\n potential focus for spread antifungal creams alone; advise oral • Oral antifungals for adults:\n of the fungus to other antifungals Tab Terbinaﬁne 250mg BD\n body sites\n OR Tab Griseofulvin 500mg BD\n Advise anti fungal creams over most Tab Fluconazole 50-150 mg OD\n bothersome lesions only (in addition to • For relief of pruritus: TREATMENT\n systemic drugs) Tab Cetirizine 10mg HS or Tab CPM 4mg\n TOPICALS\n TREATMENT IN CHILDREN TDS\n • Always look for infection in the\n TREATMENT IN PREGNANCY • Limited disease with less than 50%\n parents/caregivers\n • Preferably use only topical antifungals nail surface involvement/ not going • Prefer topical antifungals for younger children\n • Maximum safety data for use of back till the lunula • Oral antifungals (weight based dosing)\n Miconazole cream • Terbinafine : 3-6mg/kg/day or\n Clotrimazole cream OR <20kg : 62.5mg \n • Limited safety data in humans to 20-40kg : 125mg\n >40kg : 250mg recommend use of any systemic antifungal • Patients with contraindication for\n • Fluconazole : 6mg/kg/day during pregnancy esp ﬁrst trimester oral antifungals(eg. renal disease etc\n • Griseofulvin : 10-20mg/kg/day • If required, ﬂuconazole may be preferred • Amorolfine 5% nail lacquer\n application once a week or\n REFER TO A SPECIALIST/ TERTIARY CENTRE IF MANAGEMENT AT TERTIARY CARE\n Ciclopirox 8% nail lacquer thrice a • Very extensive disease • Individualise treatment\n • No/ minimal improvement with regular week • Treat till complete clinical and mycological\n treatment after 4 weeks\n cure (KOH negativity) • Cure not achieved despite prolonged treatment SYSTEMIC ANTIFUNGALS\n and good compliance • Send for culture, speciation and antifungal\n • Recurrent infection susceptibility testing, if available • Tab Terbinafine 250mg BD (6 weeks\n • Co-morbid conditions present: for fingernails and 12 weeks for\n Pregnancy/lactation/hepatic disease/renal toenails)\n disease or cardiac disease TOPICAL TREATMENT (OVER LIMITED AREAS ONLY) • Cap Itraconazole 100 mg BD for 12\n • History of prolonged topical/ oral/parenteral/ • In addition to previously mentioned:\n weeks\n steroid use • Luliconazole cream topically OD\n • Remember: The lesions are often modiﬁed by • Sertaconazole cream topically BD\n OR self application of topical steroids/ combination\n products\n • The “ring” may be incomplete 200mg BD/day for seven days a SYSTEMIC TREATMENT\n • Scaling may be minimal • Cap Itraconazole 100-200 mg/day month (2 such pulses for ﬁngernails\n • Pigmentation may be prominent\n • Tab Terbinaﬁne 250mg BD and 3 for toe nails) • Do not use any steroid containing cream\n\n ENSURE TREATMENT FOR ADEQUATE DURATION TO PREVENT RELAPSE",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg14",
    "doc_id": "1725967364_dermatology_all",
    "page": 14,
    "text": "2022\n\n Standard Treatment Workﬂow (STW)\n ECZEMA/ DERMATITIS\n ICD-10-L20\n\n ACUTE MAJOR FORMS OF ECZEMA\n Red, edematous plaques with EXOGENOUS ECZEMAS ENDOGENOUS ECZEMAS\n small, grouped vesicles Those with a known exogenous Without a known exogenous trigger,\n trigger, management of more often requires pharmacological\n exogenous eczemas is to remove intervention\n the cause if possible, along with\n pharmacological intervention • Asteatotic eczema\n SUBACUTE • Atopic eczema\n Erythematous plaques with • Allergic contact eczema • Chronic superﬁcial scaly eczema\n scaling or crusting • Dermatophytide • Eyelid eczema\n • Eczematous polymorphic light • Hand eczema\n • Juvenile plantar dermatosis eruption\n • Nummular eczema • Infective eczema\n • Pityriasis alba\n CHRONIC • Irritant contact eczema\n • Eczema associated with systemic Lesions may have scaling or • Photoallergic contact eczema disease\n licheniﬁcation • Post‐traumatic eczema • Seborrhoeic eczema\n • Venous eczema\n\n HISTORY\n • Associated history of atopy, allergic rhinitis or asthma in patient and family members\n • Age of onset is usually early( less than 5 years) in atopic dermatitis\n • Site of onset- predominant ﬂexural involvement in atopic dermatitis\n • Possible allergens implicated\n • High risk occupations with increased exposure to allergens or irritants such as agricultural work, masons,\n hair-dressers etc.\n • Associated photosensitivity, especially in parthenium dermatitis\n • Change in severity with season; summer exacerbation in parthenium dermatitis\n • Winter exacerbation in atopic dermatitis\n EXAMINATION\n ATOPIC DERMATITIS ENDOGENOUS ECZEMA CONTACT DERMATITIS\n• Infantile: Most commonly on the • Nummular\n • It can be face, followed by involvement of dermatitis/eczematous: irritant or extensors of the knees and\n Circular or oval, allergic elbows\n commonly affecting • Eczema• Childhood/ Adult phase: Pattern\n pattern changes to ﬂexural involvement neck, hands and feet\n corresponds (cubital and popliteal fossa) • Seborrhoeic dermatitis:\n to the pattern\n Involvement of the of allergen/\n scalp and other irritant\n seborrhoeic areas exposure\n and skin folds; • It can be\n localized or ranging from mild\n widespread\n ﬂaking to thicker,\n EXAMPLE:\n yellow, greasy scales Parthenium\n and crusts dermatitis\n • Venous eczema: Eczema affecting the medial contact\n aspect of ankles associated with varicose dermatitis\n veins/ venous incompetence to nickel\n contact\n dermatitis to\n ATOPIC DERMATITIS hair dye\n DIAGNOSIS\n • Most cases of eczema can be diagnosed clinically\n • Secondary infection is common, may cause eczema to ﬂare and can be conﬁrmed by taking swabs for culture\n and sensitivity\n • Patch tests are designed to detect allergens in cases of suspected allergic contact dermatitis\n • Potassium hydroxide (KOH) preparation or biopsy when dermatophyte infection or other diagnoses are\n suspected\n DIFFERENTIAL DIAGNOSIS\n • Tinea corporis\n • Psoriasis\n • Cutaneous t-cell lymphoma (CTCL)\n TREATMENT\n GENERAL PRINCIPLES SPECIFIC MANAGEMENT\n • Avoidance of allergens and irritant materials Primary/Secondary Level\n • Daily bath with mild soap, keep nails short, avoid • Treatment of active eczema: Daily use of TCS of appropriate\n scratching strength until completely clear ± antihistamine (for\n • Moisturizer are cornerstone in the management of\n sedative/antipruritic effects) ± oral antibiotic course (if\n eczema; to be applied immediately after bathing\n superinfection) - (refer to STW on rational use of topical while the skin is still damp and apply multiple times\n therapy) during the day\n • Maintenance treatment for area where lesions are more • Antihistamines for (eg. levocetirizine) for control of\n pruritus resistant to treatment or there is propensity for relapse, like\n • Topical corticosteroids (TCS) mild – Over face/ ﬂexural skin- Intermittent use of mid-potency TCS (e.g. 2-3\n ﬂexures genitals. Mid potent TCS over palms, soles days/week) and/or TCI (e.g. 3–5 days/week)\n and licheniﬁed lesions\n • Topical calcineurin inhibitors (TCIs)- Face/ ﬂexures Tertiary Level\n genitals and/or as maintenance treatment • Severe disease in addition to above may require\n • If secondary infection (pain, pus discharge, yellow phototherapy or systemic treatment (Short course of oral\n crust)- Treat with topical/ oral antibiotic as needed\n corticosteroids, cyclosporine, azathioprine etc.)\n\n AVOIDANCE OF PROVOKING AGENTS, MOISTURIZERS AND EARLY TREATMENT ARE THE AIM OF ECZEMA MANAGEMENT",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg15",
    "doc_id": "1725967364_dermatology_all",
    "page": 15,
    "text": "2022\n\n Standard Treatment Workﬂow (STW)\n IMMUNOBULLOUS DERMATOSES\n ICD-10-L13.8\n\n Appearance of ﬂuid-ﬁlled, itchy AUTOIMMUNE BLISTERING DISEASES ADDITIONAL INFORMATION\n or painful blisters (either • Pemphigus vulgaris/ variants • Age at onset and duration of\n ﬂaccid or tense) on skin, over a • Pemphigus foliaceus/ variants blistering normal or erythematous base\n • Bullous pemphigoid • History of any recent drug\n • Pemphigoid gestationis\n WHEN TO intake • Mucous membrane pemphigoid Appearance of raw, • History of prior varicella/ SUSPECT? erythematous erosions ± • Linear IgA bullous diseases/ chicken pox\n crusting on skin chronic bullous disease of\n • History of similar illness in\n childhood\n family • Dermatitis herpetiformis\n • History of itching, pain, burning Appearance of erosions/ • Epidermolysis bullosa acquisita\n blisters inside oral cavity, eyes, • Bullous systemic lupus • Predominant sites affected\n nose and genitals erythematosus • Associated photosensitivity\n\n EXAMINATION DIAGNOSIS OF AUTOIMMUNE BULLOUS DISEASES\n\n • Are the blisters ﬂaccid or tense? • Likely pemphigus group of autoimmune bullous diseases\n • Are the erosions crusted? > Flaccid blisters/ erosions ± crusting on skin ± mucosae\n\n > • Do the blisters contain clear or hemorrhagic Usually seen in adults; can rarely affect children\n ﬂuid? • Likely sub-epidermal autoimmune bullous diseases\n • Are the blisters umbilicated? > Tense, small to large blisters, containing clear or hemorrhagic ﬂuid, on an itchy\n • Is the base of the blisters erythematous/ erythematous base, commonly healing with hypopigmentation ± scarring\n urticarial? > Seen in children, adults and elderly (most common is bullous pemphigoid)\n • Are the blisters healing with or without scarring?\n • Are they healing leaving behind • Get a Tzanck smear\n hyper/hypopigmentation? • Get a biopsy for histopathology from margin of a lesion\n • What is the color of the crust? • Get a peri-lesional biopsy for direct immunoﬂuorescence, if facility is available\n • Are mucosae involved?\n\n • Child < 5 years\n • Erosions with peripheral tense\n blisters\n • Urticarial base\n • Face/ peri-genital\n involvement\n\n PEMPHIGUS BULLOUS PEMPHIGOID CHRONIC BULLOUS DISEASE OF CHILDHOOD\n DIFFERENTIAL DIAGNOSES\n RED FLAG SIGNS\n • Bullous Impetigo, Varicella, Stevens Johnson\n • Fever ± chills and rigors Syndrome/TEN*\n • Hypotension (indicating • Epidermolysis bullosa, a hereditary blistering disease\n hypovolemia due to with onset in neonatal period or infancy and\n ﬂuid loss or sepsis) predominantly affecting pressure sites; presence of\n scarring on limbs, acral areas, trunk and abnormality of • Altered sensorium\n the teeth or nails (indicating\n • Consider Congenital syphilis in a neonate- get VDRL for\n dyselectrolytemia or\n mother and child\n sepsis) *Refer to STW on Bacterial Infections; Varicella and\n Herpes Zoster and cADR Part B EPIDERMOLYSIS BULLOSA\n GENERAL MEASURES\n• Monitor temperature, respiratory rate, pulse rate • Maintain oral hygiene (if involved)\n\n >• Administer antibiotics if lesions are infected and foul smelling Chlorhexidine mouth wash\n• Fluid-electrolytes balance > Brush teeth with pediatric brush with small head and soft bristles\n• Get hemogram, basic biochemistry including renal and hepatic > Avoiding eroding gingival margin\n function tests, blood sugar • Maintain skin hygiene (if involved)\n• Get pus culture and if sepsis is suspected, also blood culture > Diluted potassium permanganate bath/ potassium\n• Supportive management permanganate compresses on localized lesions/ thick crusted\n > Clean non-adherent dressings lesions\n > Maintain hygiene with normal soap bath > Emollients/ coconut oil application\n > Topical antibiotics > 2% savlon scalp wash\n > Aspiration of large blisters with 18G needle if needed • Encourage oral intake (ﬂuids and calories); consider other\n > comorbidities Avoid derooﬁng the blisters as the roof of the blister acts as\n a natural dressing > Liquid/ semisolid diet for oral erosions\n\n PEMPHIGUS (START TREATMENT ONLY IF FACILITY FOR MONITORING AND BULLOUS PEMPHIGOID (START TREATMENT ONLY IF FACILITY FOR MONITORING\n MANAGEMENT OF COMPLICATIONS OF TREATMENT IS AVAILABLE) AND MANAGEMENT OF COMPLICATIONS OF TREATMENT IS AVAILABLE)\n• Mucosal/ mucocutaneous with body surface area <5% • Limited (<10% body surface area)\n • Oral Prednisolone (0.5 mg/kg/day), with one or more of the • Start treatment and refer to tertiary level\n following • Topical Clobetasol propionate (upto 30 gm/day)\n > Azathioprine (2-3 mg/kg/day) • Oral Prednisolone (0.5 mg/kg/day) ±\n > Mycophenolate mofetil (35mg/kg/day, start at a lower > Dapsone (100-150 mg/day)\n dose) > Doxycycline (100- 200 mg/day)\n > Cyclophosphamide (1-2 mg/kg/day) > Niacinamide (500 mg thrice/day)\n > Methotrexate (0.3mg/kg/week) > Azathioprine (2-3 mg/kg/day, start at a lower dose)\n > Dapsone (100-150 mg/day) > Mycophenolate mofetil (35mg/kg/day, start at a lower dose)\n• Mucocutaneous with body surface area >5% > Methotrexate (0.3mg/kg/week)\n • At primary level-Stabilize patient, initiate general measures • Extensive (>10% body surface area)\n and refer to a specialist/ tertiary level • To be managed at a tertiary level\n • To be managed at a tertiary level • Oral Prednisolone (0.75- 1 mg/kg/day) ±\n > Dexamethasone- Cyclophosphamide pulse therapy > Dapsone > Doxycycline > Niacinamide\n > Rituximab > Azathioprine > Mycophenolate mofetil > Methotrexate\n\n CORRECT DIAGNOSIS PREVENTION/ TREATMENT OF SEPSIS AND REGULARITY OF TREATMENT BRINGS BEST RESULTS",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg16",
    "doc_id": "1725967364_dermatology_all",
    "page": 16,
    "text": "2022\n\n Standard Treatment Workﬂow (STW)\n PSORIASIS\n ICD-10-L40\n\n *GENERAL PRINCIPLES OF MANAGEMENT TREATMENT OVERVIEW\n • Establish the diagnosis TOPICAL THERAPY {<5% BODY\n ▶ Usually clinical and by bed side tests (Auspitz sign, Grattage test) SURFACE AREA (BSA)}\n ▶ If in doubt, refer to higher centre for evaluation & skin biopsy • Moisturizers like white soft parafﬁn\n • Assess for psoriatic arthritis and metabolic syndrome (obesity, dyslipidemia, diabetes, • Topical corticosteroids, Tacrolimus\n hypertension) ointment, Tazarotene, Calcipotriol, Coal\n • Counsel about variable natural course of disease and expected treatment outcome, tar, Dithranol, Salicylic acid\n and lifestyle modiﬁcations (including weight reduction, avoidance of smoking and combinations\n alcohol) PHOTOTHERAPY (>5% BSA/\n • Assess for requirement of systemic treatment, in addition to topical treatment PALMOPLANTAR PSORIASIS)\n • Advise regular use of emollients/ moisturizers. Antihistamines if pruritic • Narrow band UVB, Targeted\n • Avoid Methotrexate and Cyclosporine A in children scheduled for live vaccines phototherapy, Topical/systemic PUVA or\n • Rule out tuberculosis, HIV, Hepatitis B and C infections before systemic Psoralens with sunlight (PUVAsol)\n immunosuppressive treatment SYSTEMIC THERAPY (>5% BSA/ SEVERE\n RECALCITRANT DISEASE/ • Pregnancy test-prior to systemic therapy (Acitretin avoided in child bearing age\n PALMOPLANTAR PSORIASIS/ group)\n ARTHRITIS) • Systemic steroids should not be given for the treatment of psoriasis, except for\n • Methotrexate/ Cyclosporine A/ generalized pustular psoriasis of pregnancy\n Retinoids-isotretinoin (may be preferred • If ﬁrst-line treatment options fail or are contraindicated, refer to tertiary care center for\n in adolescent girls), Acitretin/ oral combination. Baseline investigations to be carried out\n antibiotics (guttate psoriasis)/ novel These principles should be used only as a general guide to choose a treatment; ﬁnal small molecules\n decision should be made on case-to-case basis • Resistant cases- Biologics\n\n PLAQUE PSORIASIS GUTTATE PSORIASIS PALMOPLANTAR PSORIASIS\n VARIANTS\n OF\n PSORIASIS\n PUSTULAR PSORIASIS ERYTHRODERMIC PSORIASIS\n\n PLAQUE PSORIASIS\n\n Erythematous plaques with silvery white scales\n\n LIMITED PLAQUE PSORIARIS (< 5%) GENERALIZED PLAQUE PSORIASIS\n\n PRIMARY/ SECONDARY LEVEL REFER TO GENERAL PRINCIPLES OF MANAGEMENT\n • Face and ﬂexures - 1% Hydrocortisone/ PREFERABLY TO BE MANAGED AT HIGHER CENTRE\n low potency steroid cream OD for 2\n weeks • Systemic treatment- • Continue emollients\n • Trunk and extremities - Betamethasone refer to treatment • Avoid irritants & cream (or any other potent steroid, overview\n preferably with Salicylic acid 3-6%) OD prolonged use of\n • If these fail or are for 2-4 weeks topical steroids\n • Other topical treatment as listed in contraindicated, refer to\n treatment overview tertiary level for\n TERTIARY LEVEL combination or Scalp- Tar based\n • Continue with topical therapy rotational therapy/ novel shampoo and topical • If the patient does not respond in 6-8\n small molecules/ steroids +/- salicylic weeks, try alternate topical agents and/\n or systemic therapy or NB UV-B/ PUVA/ biologicals acid lotions\n PUVAsol\n\n GUTTATE PSORIASIS\n\n TREATMENT CLINICAL FEATURES\n • Shower of numerous REFER TO GENERAL PRINCIPLES OF MANAGEMENT*\n erythematous Primary health centre/Level Tertiary Level papules < 1 cm on the • Antibiotics for streptococcal\n • Same as primary level care trunk and extremities infection\n • Seen more • Narrow band UVB\n Secondary Level commonly in • Refractory cases- consider systemic\n • Same as primary level care younger patients • Psoralen ultraviolet A Solar (PUVAsol) treatments including novel small molecules\n\n PALMOPLANTAR PSORIASIS\n Chronic erythematous well deﬁned plaques symmetrically on palms and soles, and occassional\n nail involvement to be differentiated from palmoplantar eczema\n\n REFER TO GENERAL PRINCIPLES OF MANAGEMENT*\n PRIMARY HEALTH CENTER SECONDARY CARE HOSPITAL AND TERTIARY CARE HOSPITAL\n • Topical petrolatum at least twice daily • In addition to those treatment prescribed at primary care\n • Add antibiotics if signs of infection • Tar based applications/ steroid-salicylic acid with\n • Potent steroid-salicylic acid occlusion (if very thick plaques) for 2-4 weeks\n combination Refer to higher center if • Phototherapy- Hand and foot NB UV-B/ PUVA soaks\n not responding in 6-8 weeks • Systemic therapy - refer to treatment overview\n\n ERYTHRODERMIC PSORIASIS PUSTULAR PSORIASIS\n\nCLINICAL FEATURES CLINICAL FEATURES\n• Generalised erythema and scaling involving • Crops of localized or generalised sterile pustules\n >90% of the BSA and lakes of pus with surrounding erythema,\n• Triggered by withdrawal of systemic\n often associated with fever corticosteroids/ potent topical steroids or HIV\n infection • In pregnancy- presents as impetigo\n• Common D/D- dermatitis, drug reactions, herpetiformis,may lead to intrauterine growth\n pityriasis rubra pilaris, idiopathic erythroderma retardation or still birth\n\n GENERAL MANAGEMENT AT PRIMARY CARE\n • Stabilize patient & treat secondary infection • High protein diet\n • Maintain temperature/ ﬂuid and electrolyte balance • Lab investigations: Complete Hemogram, Liver & Kidney Function test\n • Admit if febrile & unstable vitals • Refer to higher center for speciﬁc management\n\n SPECIFIC MANAGEMENT\n • Assess patient SPECIFIC MANAGEMENT\n • Take drug history (particularly Beta-lactams, Macrolides, Calcium channel\n • Skin biopsy, if in doubt blockers) to rule out acute generalized exanthematous pustulosis\n • Methotrexate or Cyclosporine A • Generalized pustular psoriasis - admit the patient and follow general\n • Maintenance- Acitretin/ NbUVB/ PUVA measures as for psoriatic erythroderma\n • In addition to blood tests as listed previously, serum calcium (patients may\n • If patient fails to respond, consider biologics have hypocalcemia) should also be estimated\n • Acitretin/ Methotrexate/ Cyclosporine\n\n PSORIASIS IS COMPLETELY TREATABLE BUT HAS A CHRONIC COURSE",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg17",
    "doc_id": "1725967364_dermatology_all",
    "page": 17,
    "text": "022\n\n Standard Treatment Workﬂow (STW)\n RATIONAL USE OF TOPICAL MEDICATIONS\n\n Most commonly prescribed GENERAL PRINCIPLES FOR TCS USE TOPICAL CORTICOSTEROIDS (TCS)\n topical medication in • Before prescribing, make sure the dermatosis is\n dermatology steroid responsive\n • Rule out fungal and bacterial infections at the\n local site\n Because of quick results, it • Super potent and potent TCS usually, for a\n has high abuse potential maximum duration of 2 weeks\n • For children and over face- only low potency TCS\n • For larger surface area, use finger tip unit (FTU)\n Unmonitored use can cause method for application of TCS\n both local and systemic • For use over smaller area, less than 1 FTU maybe\n adverse effects\n required; advise not to apply beyond the lesion\n\n COMMON TOPICAL FORMULATIONS AND THEIR USAGE DOSE AND AMOUNT\nTopical formulation Key aspects of usage\n Educate the patient about the optimum\nCream Emulsion of oil and water; preferred for oozy/wet lesions quantity (in grams) of TCS required\nOintment Semi-solid, greasy, occlusive; preferred for better\n A single application to the whole body of an penetration, especially over thick keratotic lesions\n adult will require 20 to 30 g of product\nGel Aqueous or alcoholic monophasic emulsion (cream/ointment/lotion)\n Liquefies upon contact with skin\n An area of one hand (palm and digits) Preferred for greater cosmetic acceptance, and hairy areas\n will require 0.3 g per application\nLotion Usually thicker than a solution and likely to contain\n oil/water/alcohol No more than 45 g/week of potent or 100\n Use lotions over hairy areas and larger body surface areas g/week of a moderately potent TCS should\n be appliedAerosol foam/spray A solution with pressurized propellant; alternative to lotion\nPowder Solid, for example, talc/corn starch; doubtful Treatment under occlusion should be\n penetration/efficacy avoided; only prescribed by specialists\n\n FINGERTIP UNIT (FTU) METHOD FACE & NECK FEW ACCEPTABLE COMBINATIONS WITH TCS\n FOR WIDESPREAD ECZEMA 21_ Should be used only in specific situations and 2\n under strict supervision\n FTU 1 • TCS+ Fusidic acid 2% cream/ointment (for\n TRUNK\n Open the tube of FRONT & BACK impetiginized eczematous lesions)\n medication ONE ARM 14 • TCS + Salicylic Acid (3-6%) ointment (for thick\n 3\n FTU hyperkeratotic eczema/psoriasis)\n FTU\n 2 • Topical Calcipotriene-TCS (for mild to moderate\n psoriasis)\n Extend your index ﬁnger ONE HAND GROIN\n facing up 1 1 • Hydroquinone 2% + Tretinoin 0.025% +\n FTU FTU Fluocinolone Acetonide 0.1% Cream (use with\n 3 great caution in melasma – high abuse potential)\n\n Squeeze out a line of medication\n from the tip of your ﬁnger to the\n ﬁrst skin crease. This is one ONE LEG\n 6\n ﬁngertip unit (see below)\n FTU\n\n This is\n 1\n Fingertip\n Unit\n ONE FOOT\n 2\n 4 FTU\n\n Apply the medication or the The ﬁgure shows the number of FTUs\n affected area required for different areas of the body TCS ‘damaged’ face TCS induced striae\n\n RATIONAL TOPICAL COMBINATIONS FOR ACNE GENERAL PRINCIPLES FOR TOPICAL ANTIBIOTIC USE IN ACNE\n\n• Clindamycin 1%+Tretinoin 0.025% gel • Benzoyl peroxide (BPO) alone, or in combinations with Retinoids/\n\n• Adapalene 0.1% +Clindamycin Clindamycin are effective for mild acne, or in conjunction with a topical\n\n phosphate 1% retinoid, or systemic antibiotic therapy for moderate to severe acne\n\n• Clindamycin 1% + Benzoyl peroxide • BPO is effective in the prevention of bacterial resistance and is\n\n 5% cream recommended for patients on topical or systemic antibiotic therapy\n\n• Adapalene 0.1% + Benzoyl peroxide • Topical antibiotics like Clindamycin are effective acne treatments, but\n\n 2.5% gel are not recommended as monotherapy because of the risk of bacterial\n\n resistance\n\n MOISTURIZERS GENERAL PRINCIPLES FOR TOPICAL SUNSCREEN USE\n\n• One of the most commonly applied topical • For photosensitive dermatoses like lupus\n\n preparations for normal skin care and in diseased skin erythematosus, liberal uniform ﬁlm of sunscreen (2\n\n to improve barrier function of skin mg/cm2) should be applied on sun-expoxed sites, and\n\n• Moisturizer alone are therapeutic in conditions like application should be atleast 15 minutes before sun\n\n eczema and psoriasis exposure\n\n• Bland, fragrance-free moisturizer should be preferred • Routine topical sunscreen use is not essential except in\n\n• Moisturizers in common use – white soft parafﬁn/light special situations with intense, prolonged sun\n\n liquid parafﬁn, glycerin with water, coconut oil exposure, such as mountaineering\n\n TOPICAL STEROIDS ARE A DOUBLE EDGED SWORD - USE JUDICIOUSLY",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg18",
    "doc_id": "1725967364_dermatology_all",
    "page": 18,
    "text": "2022\n\n Standard Treatment Workﬂow (STW)\n SCABIES\n ICD-10-B86\n\n OTHER PRESENTATIONS SYMPTOMS AND SIGNS\n • Intense itch that is worse at night • Extremely itchy, persistent nodules\n may develop over male genitalia • Other members of the family are\n often also affected • Secondary bacterial infection can\n occur in those with poor hygiene, • Scabies is an infestation by a • Red, itchy papules and excoriations\n mite - Sarcoptes Scabiei var are seen mainly over ﬁngers especially in children\n hominis (interdigital spaces), wrists, • CRUSTED SCABIES\n • Transmission occurs by skin to periumbilical area, breasts, buttocks, > Severe form of scabies that\n axillary folds, waist, genitalia, and develops in those with skin contact, sexual contact and\n predisposing factors such as extensor aspects of the limbs infested fomites (like towels, immunosuppression (due to • The face, palms and soles are clothes, beddings) disease or drugs - including\n usually spared in adults; but • Symptoms start 3-6 weeks after topical steroids), neurological\n typically involved in young children primary infestation but faster disorders, or physical\n • Burrow is the most characteristic incapacitation or mental (2-3 days) after a re-infestation\n lesion of scabies, but is often not retardation- associated inability • Multiple cases may occur in\n observed to scratch schools /orphanages and other\n • Burrows should be looked for in > Thick, yellow brown crusts form such cluster settings\n web spaces and wrists and appear that are densely packed with\n mites as thin, brown-grey lines of 0.5–1 cm\n • Sometimes, vesicles are also seen > The thick crusts may be\n localised to hands and feet • Lesions may be sparse in those with\n (including nails) a good hygiene\n\n Excoriated papules at the typical sites – breasts, abdomen, web spaces of ﬁngers and wrists\n\n DIAGNOSISDIAGNOSIS\n •• DiagnosisDiagnosis isis usuallyusually clinicalclinical\n •• DemonstrationDemonstration ofof mite,mite, mitemite\n eggs,eggs, oror mitemite faecesfaeces (scybala)(scybala)\n maymay bebe attemptedattempted fromfrom\n burrowsburrows (if(if visible)visible) oror byby\n dermoscopydermoscopy (if(if available)available) andand\n fromfrom thethe thickthick crustscrusts inin casecase ofof\n crustedcrusted scabiesscabies (where(where mitemite isis\n easilyeasily demonstrable)demonstrable) Scabies mite in KOH Crusting in ﬁnger webs in localised crusted scabies smear (400X)\n TREATMENT\n GENERAL MEASURES Most patients are treated with topical alone\n • Permethrin 5% cream: Apply over the whole skin surface (neck downwards) on dry\n• All family members and close\n and clean skin; wash off after 8-12 hours (advice to apply late evening and keep\n contacts must be overnight)\n simultaneously treated to • In infants, the face and scalp must also be treated\n > Special attention must be given to interdigital webspaces, axillae, area under prevent re-infestation\n the ﬁngernails and toenails the wrists the external genitalia and the buttocks\n• The clothes and other fabrics > To ensure 8 hours of contact time, Permethrin should be re-applied if hands are\n such as towels and bed linen washed\n used by the patient in > About 30 grams of cream is used for one application in adults and children ≥ 5\n years; 15 grams for children < 5 years preceding three days must\n > The application is to be repeated after 7–14 days\n be washed with hot water • Alternatively, 1% Gamma Benzene Hexa-Chloride (GBHC/ lindane): may be used for\n and dried in the sun application as above for permethrin. Avoid use in infants\n Oral treatment for patients with poor compliance or response to topicals therapy• The items may also be kept\n • Oral Ivermectin: at a dose of 200 mcg/kg (upto 12 mg); two doses 1 week apart; taken\n sealed in a plastic bag for\n with food\n atleast 3 days (also useful for • Avoid Ivermectin in infants, children < 5 years old or <15 kg, and in pregnancy.\n shoes and other non Permethrin has been safely prescribed in these situations\n • Antihistamines should be prescribed as per the patient’s requirement washable items)\n\n• Treatment of secondary infection (Staphylococcal/ Streptococcal): Refer to Bacterial skin infection STW\n• Treatment of crusted scabies: Ivermectin on days 1, 2, 8,9 and 15 (additionally on days 22, 29 days in severe cases)\n with Permethrin 5% cream daily for 7 days, then twice weekly until cure. A keratolytic such as 3-6% Salicylic acid\n may be used over crusts\n• Nodular lesions: Potent topical steroid (Clobetasol propionate) or intralesional steroid (Triamcinolone acetonide\n 10 mg/mL) may be required for persistent nodules\n\n POST TREATMENT ADVISE\n • The patients must be explained that itching can continue for several weeks after successful treatment and\n repeated applications are not required; continue antihistamines for symptomatic management\n • However, if itching persists for more than 3-4 weeks/ or if new lesions are noted - a reinfestation is likely. This can\n occur if all close contacts were not simultaneously treated\n\n TREAT THE ENTIRE SKIN, NOT LESIONS ALONE; TREAT THE FAMILY/CONTACTS, NOT THE PATIENT ALONE",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg19",
    "doc_id": "1725967364_dermatology_all",
    "page": 19,
    "text": "022\n\n Standard Treatment Workﬂow (STW)\n URTICARIA AND ANGIOEDEMA\n ICD-10-L50.9\n\n URTICARIA-CLINICAL APPEARANCE HISTORY\n• Urticaria -sudden appearance of wheals, angioedema, or both • Time to onset • Drug history\n• A wheal- A sharply circumscribed superﬁcial central swelling of • Frequency / duration • Correlation with food\n variable size and shape, surrounded by reﬂex erythema • Diurnal variation\n > Associated with itching / burning sensation and of ﬂeeting • Correlation with menses\n • Associated angioedema nature- resolves within 1–24 hours • Smoking\n > Chronic urticaria implies duration for more than 6 weeks • Associated pain, itch • Work proﬁle\n• Angioedema • Induction by physical agents or exercise\n > • Hobbies Sudden, pronounced, erythematous or skin-colored swelling of • Family history\n lower dermis and subcutis with frequent involvement of • Stress • Previous allergies\n mucous membranes\n • Quality of life impact > • Surgical implantations Associated pain, rather than itching /resolution is slower and\n can take up to 72 hours • Gastric / intestinal problem • Response to therapy\n CLASSIFICATION OF CHRONIC URTICARIA SUBTYPES\n EXAMINATION (presenting with wheals, angioedema, or both)\n\n Chronic spontaneous Inducible (mostly physical) • Due to evanescent nature the examination may not show any lesions\n • Spontaneous • Symptomatic dermographism • Presence of wheals of various sizes and shapes\n appearance of wheals, • Delayed pressure urticaria\n • The lesions are non-scaly but show an intense erythema and a trailing • Cholinergic urticaria angioedema, or both\n • Cold/Heat urticaria clearing region in older areas which may lead to a target conﬁguration in for ≥6 weeks • Solar urticaria\n expanding plaques\n • Aquagenic urticaria\n • Contact urticaria\n DIFFERENTIAL DIAGNOSES OF URTICARIA\n\n • Insect /Bedbug bites\n\n • Urticarial vasculitis- painful, persist for\n\n 24-48 hours and fade to leave bruising;\n\n ± fever and arthralgia\n\n • Pre bullous phase of bullous\n\n pemphigoid\n\n • Maculopapular drug/ viral rash\n\n URTICARIA URTICARIAL VASCULITIS\n INVESTIGATIONS\n INVESTIGATIONS GENERAL PRINCIPLES\n Generally, no investigations are needed to conﬁrm the diagnosis • Reassure -remits spontaneously in 12-24 months in ~50% patients\n • Skin biopsy may be indicated if other diagnoses are being suspected • Treat with antihistamines. Reassure that prolonged treatment with\n • C4 and C1 inhibitor quantitation to detect C1 inhibitor deﬁciency may long-acting, non-sedating antihistamines is not harmful\n be done in suspected hereditary angioedema (Angioedema without\n • Non-sedating antihistamines (e.g. Cetirizine 10mg, Levocetirizine 5mg, urticaria)\n Loratadine 10mg, or Fexofenadine 180mg once daily) mainstay of • Tests for current or past viral, bacterial or parasitic infections should\n be guided by history and clinical ﬁndings treatment. Dose can be increased 4-fold safely if needed\n • Lab tests may be needed if patient is planned for • Long-term ﬁrst generation antihistamines e.g. Chlorphenamine,\n immunosuppressive treatment Hydroxyzine avoided if possible due to risk of sedation and psychomotor\n • Certain investigations that are often ordered, but are of limited utility impairment\n > Thyroid function tests and antithyroid peroxidase (TPO) antibodies • Avoid triggers including drugs such as NSAIDs, PCM, ACE inhibitors if\n > Autologous serum skin test (ASST) history is suggestive of drug induced or exacerbated urticaria/\n\n > Skin prick / speciﬁc IgE test angioedema\n TREATMENT\n\n TREATMENT OF URTICARIA/ANGIOEDEMA* • Severe urticaria with respiratory distress- REFER TO A HIGHER CENTRE\n AT PRIMARY CARE LEVEL maintain airway; injectable Hydrocortisone\n • Patients whose urticaria is difﬁcult to and Pheniramine (Avil) may be required\n First Line: control with antihistamines despite • Intra-muscular Adrenaline of 1:1000 dilution\n 2nd generation non-sedating fourfold higher dosage than the licensed (1 mg in 1 mL), 0.2 to 0.5 mg (0.01 mg/kg in\n antihistamines\n children; maximum dose: 0.3 mg) doses of Cetirizine, Levocetirizine or\n If symptoms persist administered intramuscularly every 5 to 15 Fexofenadine after 2 weeks\n minutes if choking/respiratory • Patients with polypharmacy Second Line:\n distress/shock Increase dosage (upto fourfold) of 2nd • Unusual urticaria e.g. long lasting lesions\n generation antihistamines * Angioedema with respiratory or laryngeal >24-48 hours with bruising\n symptom requires emergency\n If symptoms persist after • Associate angioedema that is\n 2–4 further weeks management -refer to higher center after\n unresponsive or presents with choking/ vital stabilization; oral Prednisolone may\n dyspnoea Refer to higher centre be initiated to take care of biphasic\n response • Investigations not available\n\n MANAGEMENT AT SECONDARY CARE LEVEL MANAGEMENT AT TERTIARY CARE LEVEL\n\n First Line: First Line:\n 2nd generation antihistamines 2nd generation antihistamines\n\n If symptoms persist after 2 weeks If symptoms persist after 2 weeks\n\n Second Line: Second Line:\n Increase dosage (upto fourfold) of 2nd generation antihistamines Increase dosage (upto fourfold) of 2nd generation antihistamines\n\n If symptoms persist after 2–4 further weeks If symptoms persist after 2–4 further weeks\n\n Add third line on to second line: Third line:\n Cyclosporine A (3-5 mg/Kg) or Montelukast (10 mg HS) Add on to second line Omalizumab (300mg s/c every 4 weeks)\n Short course (max 10 days) of corticosteroids or Cyclosporine A or Montelukast\n (Prednisolone-0.3-0.5 mg/kg)# Short course (max 10 days) of corticosteroids #\n\n #Oral or injectable conticosteroids are generally not used, except in uncontrolled disease or with associated respiratory symtoms\n\n URTICARIA TREATMENT GOAL IS DISEASE REMISSION-NOT CURE",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg20",
    "doc_id": "1725967364_dermatology_all",
    "page": 20,
    "text": "2022\n\n Standard Treatment Workﬂow (STW)\n VARICELLA & HERPES ZOSTER\n ICD-10-B01-02\n\n VARICELLA (CHICKEN POX) HERPES ZOSTER\n\n WHEN TO SUSPECT? WHEN TO SUSPECT?\n • Fever, malaise • Acute, grouped, vesiculo-pustular eruption in a\n • Generalized vesicular lesions on erythematous base (dew drop dermatomal distribution\n on a rose petal sign) • Dermatomal pain\n • Skin lesions in different stages of evolution: erythematous\n TAKE HISTORY OF macules, papules, vesicles and crusted lesions\n • Previous varicella\n TAKE HISTORY OF • Previous episode of herpes zoster\n • Recent contact with a patient with varicella • Immunosuppression: Diabetes mellitus, malignancy,\n • Past history of varicella/ varicella vaccination transplant recipient, HIV\n • Immunosuppression (especially if second episode of varicella):\n malignancy, HIV/AIDS, transplant recipient RED FLAG SIGNS\n • V dermatomal involvement: forehead, periorbital,\n PREGNANCY AND VARICELLA nose tip: risk of eye involvement - look for watering of\n • Infection in 1st 20 weeks may lead to congenital varicella\n eye, redness, photophobia\n syndrome\n • Lesions on the ear or inside the ear canal: risk of\n • Treat with acyclovir\n facial/vestibulocochlear nerve palsy - look for vertigo,\n • Maternal perinatal varicella may lead to neonatal varicella;\n tinnitus, hearing loss, facial asymmetry/weakness\n initiate treatment and refer to a specialist\n • Multi-dermatomal involvement\n • Disseminated herpes zoster\n RED FLAG SIGNS AND SYMPTOMS • Hemorrhagic/necrotic lesions\n • Hemorrhagic vesicles\n • Difﬁculty in breathing\n • Chest pain INVESTIGATIONS\n • Abdominal pain • Diagnosis is usually clinical\n • Stiff neck, confused behaviour (CNS symptoms) ▶ Tzanck smear: from a fresh vesicle- will show\n • Hemodynamic instability multinucleate giant cells and acantholysis\n • Optional\n INVESTIGATIONS ▶ PCR from vesicular ﬂuid\n • As per availability and need:\n ▶ Tzanck smear: from a fresh vesicle- will show\n multinucleate giant cells and acantholysis\n ▶ Symptom directed: Chest X-ray, ECG, ECHO,\n transaminases, renal function test, brain imaging\n • Optional\n ▶ VZV PCR – skin swab\n ▶ Skin biopsy\n\n TREATMENT\n • Analgesics: Acute pain relief with NSAIDs.\n • If uncontrolled, add the following (step wise):\n a) Pregabalin 150-600mg/day, start with 150mg HS and\n titrate up as required\n b) Gabapentin: start with 300mg/day, gradually increase\n upto 1800mg/day; more adverse effects than\n pregabalin\n c) Amitriptyline: 10-25mg HS\n TREATMENT d) Nortryptyline: start with 10-25mg/day; gradual increase\n • General measures upto 30-75mg/day in divided doses or HS\n ▶ Isolate the patient from high risk contacts e) Carbamazepine 200 mg HS to start with\n ▶ Daily bath with soap • Speciﬁc treatment*\n ▶ Antipyretics: Paracetamol; avoid aspirin as it is associated ▶ Acyclovir **800mg ﬁve times a day x 7 days or\n with Reye’s syndrome in children ▶ Valacyclovir 1gm three times a day x 7 days\n ▶ Antihistamines\n *Start <72 hours of onset for maximum beneﬁt, can consider if new lesions are still\n • Speciﬁc treatment* appearing after 72 hours/ Herpes Zoster ophthalmicus/Ramsay Hunt syndrome\n ▶ Adults/children >40kg: Oral Acyclovir- 800mg, 5 times a **Intravenous Acyclovir if multi-segmental involvement or disseminated zoster or\n systemic complications day for 5-7 days\n ▶ Children <40kg: (20mg/kg/dose) max 800mg four times\n COMPLICATIONS a day for 7 days\n ▶ • Secondary skin infections Alternative (if available): Valacyclovir (adults-1g TDS)\n ▶ • Herpes zoster ophthalmicus: risk when lesions present over Give intravenous Acyclovir (10mg/kg/dose 8 hourly) if:\n side/tip of nose (Hutchinson’s sign) → Systemic complications\n • Ramsay Hunt syndrome: Facial nerve palsy (with vesicles in → Hemorrhagic varicella\n the ear canal) → Immunosuppressed patient\n • Aseptic meningitis, encephalitis: In elderly and → Neonatal Varicella (higher dose may be required)\n immunosuppressed mainly\n *Infants, children >12 years of age, adults, pregnant women and immunosuppressed patients • Post-herpetic neuralgia (pain persistent for more than three should be treated with speciﬁc anti-viral medication because of risk of severe varicella\n *Maximum beneﬁt if acyclovir initiated 24 hours of onset of rash months, common in elderly)\n\n COMPLICATIONS WHEN TO REFER TO A HIGHER CENTRE WHEN TO REFER TO A HIGHER CENTRE\n • Secondary skin infections • Diagnosis in doubt • Multi-dermatomal distribution/ disseminated Herpes\n • Pneumonia • Systemic complications Zoster syndrome\n • Encephalitis • Hemodynamic instability • Systemic complications\n • Hepatitis • Hemorrhagic varicella ▶ Facial nerve palsy\n • Pancreatitis • Not responding to oral Acyclovir ▶ Eye involvement\n • Myocarditis • Immunosuppressed patient ▶ Neurological involvement\n • Reye’s syndrome • Neonatal varicella syndrome • Post-herpetic neuralgia\n\n PREVENTION\n VARICELLA HERPES ZOSTER\n◆ Active immunization (live vaccine) ◆ Passive immunization • Active immunization may be\n • <13 years old: 1st dose at 12-15 • Varicella zoster immunoglobulin may be considered offered to patients >50 years old,\n months, 2nd dose at 4-6 years where active immunization is contraindicated (pregnant irrespective of previous history of\n • >=13 years old: 2 doses weeks apart women, immunosuppressed patients) herpes zoster\n\n INITIATE SPECIFIC ANTIVIRAL TREATMENT AT THE EARLIEST TO PREVENT COMPLICATIONS",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg21",
    "doc_id": "1725967364_dermatology_all",
    "page": 21,
    "text": "2022 \n\n Standard Treatment Workﬂow (STW)\n VITILIGO\n ICD-10-L80\n\n Vitiligo is an acquired skin disease characterized by depigmented (white) macules, with a global prevalence of 1-2%\n\n NON-SEGMENTAL VITILIGO SEGMENTAL VITILIGO\n GENERALIZED VITILIGO ACROFACIAL VITILIGO OTHER VARIANTS • Unilateral with a midline demarcation\n • Lesions in a generalized • Affects the distal • Focal • Onset in childhood\n • Leucotrichia both within and distribution, usually extremities and/or • Follicular\n beyond the lesion affecting trunk, face/genitals • Mucosal\n • Usually stabilizes within a year after\n extremities and face • Less responsive to • Universal ≥ 80%\n an initial period of progression\n • No predilection for any treatment of body surface • Response to medical treatment is\n speciﬁc site; also called area variable and most patients may require\n vitiligo vulgaris involvement surgical treatment\n\n Progressive vitiligo with Generalized vitiligo Koebner’s phenomenon Acrofacial vitiligo Universal vitiligo Segmental vitiligo\n\n GENERAL PRINCIPLES OF MANAGEMENT\n\n• Diagnosis is clinical • Extensive stable/slowly progressive vitiligo:\n• Educate patient about the disease → Narrow-band ultraviolet B (NbUVB), oral Psoralen +\n• Assess the psychosocial impact of vitiligo and counsel about the Ultraviolet A (PUVA)/PUVAsol\n variable/ unpredictable course of disease & expected response to • Rapidly progressive vitiligo (limited or extensive):\n treatment → Oral corticosteroids (minipulse) and/or\n• In pregnancy, prefer only topical corticosteroids → Azathioprine/ Methotrexate\n• Decide the treatment plan based on\n A. Disease activity • Non-responders:\n ▷ Progressive: new lesions, or spread of existing lesions > Consider combining different modalities if unsatisfactory\n → Rapidly progressive: >5 new lesions in last 1 month, or >15 response with monotherapy\n lesions in last 3 months > Consider surgical treatment for stable limited vitiligo/\n → Slowly progressive: <5 new lesions in last 1 month, or < 15 lesions segmental vitiligo (unresponsive to medical treatment)\n in last 3 months > Consider camouﬂage for poorly responsive vitiligo lesions\n ▷ Stable: no new lesions, no spread of existing lesions • Monitoring of patients on systemic treatment\n B. Extent of involvement: limited (≤5%) or extensive (>5%) > Height (children), weight, blood pressure and blood sugar in\n• Limited stable/slowly progressive vitiligo: patients on oral corticosteroids\n → Topical treatment- Mid-potent/potent corticosteroids, tacrolimus, > Complete Hemogram, Liver Function Test in patients on\n topical PUVA/PUVAsol (Avoid prolonged use) drugs such as Azathioprine, Methotrexate\n\n COMMON DIFFERENTIAL DIAGNOSES IMPORTANT COUNSELLING POINTS\n\n • Leprosy • Not the same as leprosy\n > Hypopigmented, not depigmented macules • Does not spread by touch\n > Overlying sensory loss • Not caused by certain foods such as milk, curd, lemon, ﬁsh\n > Enlarged peripheral nerves etc\n • Pityriasis alba • Treatment is available for vitiligo\n > Hypopigmented scaly lesions usually on a child’s face • Multifactorial, predominantly autoimmune\n • Nevus depigmentosus\n > Present since birth or early childhood\n > Single hypopigmented macule/ segmental lesion\n\n TREATMENT\n\n REFER TO GENERAL PRINCIPLES OF MANAGEMENT\n\n Stable Primary /secondary Level Tertiary Level\n • Face, ﬂexures, genitals: Tacrolimus 0.1% • Same as in primary/secondary care\n ointment BD • Topical PUVA/PUVAsol\n • Other body sites: Betamethasone valerate/ • Handheld NbUVB\n Mometasone/ Fluticasone/ Fluocinolone • Targeted phototherapy/Excimer LASER\n cream OD (clobetasol NOT to be used) • Surgical management – minipunch grafting, suction blister Acrofacial\n • Refer non-responders to higher center epidermal grafting, noncultured epidermal suspension vitiligo\n after 3 months\n\n Progressive Refer to higher center • Topical PUVA/PUVAsol/ Handheld NbUVB (slowly progressive)\n • Levamisole (slowly progressive)\n • Oral steroid (minipulse) and/or Azathioprine/Methotrexate\n (rapidly progressive)\n\n Stable Primary /secondary Level Tertiary Level\n • Face, ﬂexures, genitals: Tacrolimus 0.1% • Same as in primary/secondary care\n ointment BD • Oral PUVA/PUVAsol\n • Other body sites: Betamethasone valerate/ • Whole body NbUVB\n Mometasone/ Fluticasone/ Fluocinolone cream\n OD (clobetasol propionate NOT to be used)\n Generalized • Refer non-responders to higher center after 3\n vitiligo months\n\n Progressive Refer to higher center • Oral PUVA/PUVAsol/ whole body NbUVB (slowly progressive)\n • Levamisole (slowly progressive)\n • Oral steroid (minipulse) and/or Azathioprine/Methotrexate\n (rapidly progressive)\n Primary /secondary Level Tertiary Level\n • Sunscreen/photoprotection • Sunscreen/photoprotection Universal\n vitiligo • Refer to higher center • Depigmenting agent like monobenzyl ether of hydroquinone 20%\n may be considered if patient wishes for complete depigmentation\n\n Primary /secondary Level Tertiary Level\n Face, ﬂexures, genitals: Tacrolimus 0.1% ointment BD • Same as in primary/secondary care\n • Other body sites: Betamethasone valerate/ • Topical PUVA/PUVAsol\n Segmental Mometasone/ Fluticasone/ Fluocinolone cream OD • Handheld NbUVB\n vitiligo\n (clobetasol propionate NOT to be used) • Targeted phototherapy\n • Refer non-responders to higher center after 3 months • Surgical management – minipunch grafting, suction blister\n epidermal grafting, noncultured epidermal suspension\n\n VITILIGO CAN BE TREATED. TREATMENT DEPENDS ON EXTENT AND ACTIVITY OF DISEASE",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg22",
    "doc_id": "1725967364_dermatology_all",
    "page": 22,
    "text": "CONTRIBUTORS \n\nADVISORY COMMITTEE\n\nCHAIRMAN\n\nProf. (Dr.) Balram Bhargava, Secretary-DHR and DGVICE CHAIRMAN\n\nDr. Nikhil Tandon, AIIMS, New Delhi\nMEMBERS\n\nDr. Anil Bhansali, Endocrinology, PGIMER, Chandigarh\n\nMrs. Anu Nagar, Jt. Secretary, Dept. of Health Research, MoHFW, Govt. of India\n\nDr. Ashok Deorari, Neonatology, AIIMS, New Delhi\n\nDr. Binod K Khaitan, Dermatology, AIIMS, New Delhi\n\nDr. Pramod Garg, Gastroenterology, TISHTI, Faridabad\n\nDr. Radhika Tandon, Ophthalmology, AIIMS, New Delhi\n\nDr. Rajdeep Singh, General Surgery, MAMC, New Delhi\n\nDr. S. C. Goel, Orthopaedics, BHU, Varanasi\n\nDr. Sandeep Agarwala, Paediatrics, AIIMS, New Delhi\n\nDr. Sudeep Gupta, Oncology, TMC, Mumbai\n\nDr. T. Sundararaman, Former Executive Director, NHSRC, New Delhi\n\nDr. Usha Dutta, Gastroenterology, PGIMER, Chandigarh\n\nEx oﬃcio Additional Secretary & MD (NHM), MoHFW, Govt. of India\n\nEx oﬃcio Director General Health Services / Representative\n\nEDITORIAL BOARD\n\nEXTERNAL COMMITTEE\n\nDr. Anil Bhansali, Endocrinology, PGIMER, Chandigarh\n\nDr. Anurag Srivastava, Oncology, AIIMS, New Delhi\n\nDr. Deepika Pandhi, Dermatology, UCMS, New Delhi\n\nDr. Neeraj Gupta, Paediatrics, AIIMS, Jodhpur\n\nDr. Radhika Tandon, Ophthalmology, RP Centre, AIIMS, New Delhi\n\nDr. Rajdeep Singh, General Surgery, MAMC, New Delhi\n\nDr. Usha Dutta, Gastroenterology, PGIMER, Chandigarh\n\nDr. Vijay Jain, Orthopaedics, RML, New Delhi\n\nINTERNAL COMMITTEE\n\nDr. R S Dhaliwal, Scientist G & Head (NCD), \n\nDr. Ashoo Grover, Scientist F, \n\nDr. Lokesh Kumar Sharma, Scientist E, \n\nDr. Aparna Mukherjee, Scientist E, \n\nDr. Jerin Jose Cherian, Scientist D, \n\nDr. Saumya Srivastava Aggarwal, Project Scientist C,",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg23",
    "doc_id": "1725967364_dermatology_all",
    "page": 23,
    "text": "DERMATOLOGY\n\nCHAIR\nDr. Binod K Khaitan, AIIMS, New Delhi\nCO-CHAIR\n\nDr. Deepika Pandhi, UCMS, New Delhi\nMEMBERS\n\nDr. Ananta Khurana, RML, New Delhi\nDr. Dipankar De, PGIMER, Chandigarh\nDr. Rahul Mahajan, PGIMER, Chandigarh\nDr. Renu George, CMC, Vellore (Retired)\nDr. Vishal Gupta, AIIMS, New Delhi",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg24",
    "doc_id": "1725967364_dermatology_all",
    "page": 24,
    "text": "CHIEF PATRON\n\nDr Mansukh Mandaviya\nUnion Minister for Health & Family Welfare\n\nPATRON\n\nDr Bharati Pravin Pawar\nUnion Minister of State for Health & Family Welfare\n\nADVISOR\n\nProf. Dr Balram Bhargava\nSecretary, DHR & Director General, \n\n STW TEAM\n\nDr R S Dhaliwal, Scientist G & Head(NCD), \nDr Ashoo Grover, Scientist F, \nDr Lokesh Kumar Sharma, Scientist E, \nDr Jerin Jose Cherian, Scientist D, \nMr Neeraj Parmar, Technical Ofﬁcer A, \nDr Saumya Srivastava Aggarwal, Project Scientist C, \nMr Dhiraj Kumar, Project Graphics Designer, \n\nADMINISTRATION\n\nShri R. Ramakrishnan, Sr DDG (Admin.), \nShri Rajeev Roy, Sr FA, \nDr R Lakshminarayanan, DDG(Admin.), \nShri Jagdish Rajesh, ADG (Admin.), \nShri Vinod Sharma, ADG(Finance),",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg25",
    "doc_id": "1725967364_dermatology_all",
    "page": 25,
    "text": "of India\n\n Scan to access Standard Treatment Workﬂows\n\n App StoreWeb Portal Google Play",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  },
  {
    "id": "1725967364_dermatology_all_pg26",
    "doc_id": "1725967364_dermatology_all",
    "page": 26,
    "text": "S T A N D A R D T R E A T M E N T\nW O R K F L O W S\n\n P A R T N E R S\n\n 2 0 2 2 E D I T I O N\n\n V O L U M E I I I",
    "metadata": {
      "type": "medical_guideline",
      "source": "1725967364_dermatology_all"
    }
  }
]